UNSPSC 51422339: Dexamethasone palmitate

This classification denotes a therapeutic glucocorticoid and antiemetic agent C38H59FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 601XWN7060, chemically known as 9-fluoro-11,17-dihydroxy-16-methyl-21-((1- oxohexadecyl)oxy)pregna-1,4-diene-3,20-dione (11.beta.,16.alpha.)-, but more generally known as dexamethasone palmitate, which bears US NIH Compound Identifier 63044. European Medicines Agency schedules Dexamethasone palmitate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01611MIG.

UNSPSC 51422339 Dexamethasone palmitate is a Commodity code that in practice captures pharmaceutical products and related health-care delivery items procured by state and local health agencies. Recent state and local solicitations under this code show purchasing of naloxone, drug deactivation systems, and pharmacy benefit management services rather than the narrower dexamethasone palmitate formulation alone, indicating that state and local procurement offices tag a broader range of pharmaceuticals and medical-supply categories under this code. Issuing bodies include county health departments and state health and human services commissions; Seminole County, Florida and the Texas Health and Human Services Commission appear in the recent record. The work spans both direct product procurement and strategic contracting for pharmacy benefit programs and direct-to-manufacturer prescription initiatives.

Geographic activity centers on Florida and Texas in the most recent opportunities. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, fixed-fee pricing, a two-year initial term with one-year renewal option, and potential FEMA funding. The Texas Health and Human Services Commission issued an RFI (HHS0017013, response deadline April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and group purchasing organization channels, emphasizing direct contracts with self-insured employers and government health plans using negotiated net pricing models. Neither opportunity specifies set-aside or disadvantaged-enterprise designations.